Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

Is Pfizer Stock Underperforming the Dow?

While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.

Barchart

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

Benzinga

Medicare Announces Price Cuts For 15 Drugs— Novo Nordisk's Wegovy And Ozempic To Cost $274 A Month

The U.S. Centers for Medicare and Medicaid Services (CMS) on Tuesday announced that it has secured lower prices for 15 of its highest‑cost medications, resulting in substantial annual savings on prescription expenses.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Simple Options Strategies to Act on Thursday’s Unusual Activity Now

Market volatility has ratcheted up in recent days. The S&P 500 was on course for its worst week in months before Friday’s open. These three strategies rely on Thursday’s unusual options activity for investors wanting to keep things simple.

Barchart

Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains

A Phase 3 study funded by Pfizer Inc. (NYSE:PFE) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential shift in how seasonal influenza is prevented.

Benzinga

Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too?

Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech. Have the good days finally come to an end?

Barchart

HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?

Hims & Hers Health may only generate a fraction of its competitors revenue, but its fiscal management and exponential growth point to a very bright future.

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

A small Texas think tank cultivated COVID dissidents. Now they’re running U.S. health policy.

People with ties to Brownstone Institute have significant authority over access to vaccines and scientific research.

The Texas Tribune

Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market

Purdue Pharma won court approval to exit bankruptcy, ending six years of litigation over its multibillion-dollar opioid settlement and the Sackler family’s liability releases. Purdue's Chapter 11 plan provides an estimated $7.4 billion to address nationwide opioid harm.

Benzinga

Ozempic Maker Novo Nordisk Faces Board Shakeup

On Friday, Novo Nordisk A/S' (NYSE:NVO) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.

Benzinga

Covid vaccines may increase the lifespan of cancer patients – this could be a game changer

A study suggests mRNA vaccines could help the body fight malignant cells, says Prof Devi Sridhar, chair of global public health at the University of Edinburgh

The Guardian - UK

Markets exhale as Novo Nordisk withdraws from Metsera bidding war

Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.

Euronews

Pfizer Metsera Acquisition: What It Means for Patients and the Future of Weight Loss

Pfizer wins the $10B bid for Metsera, opening new avenues for obesity treatment and addressing unmet healthcare needs with next-generation medicines.

International Business Times UK

Pfizer clinches deal for obesity drug developer Metsea after a bidding war with Novo Nordisk

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war against Novo Nordisk

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Deal Dispatch: From A Founder Comeback To Billion-Dollar Bids, This Week In M&A And Bankruptcy

For the previous edition of Deal Dispatch, click here.

International Business Times

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

The Guardian - UK

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

International Business Times UK

Big Short's Michael Burry Places $1B Put Orders Against Nvidia and Palantir in Q3, Warns of AI Bubble

Michael Burry's Scion Asset Management bets against Nvidia and Palantir, raising concerns of an AI market bubble despite their strong performance.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Covid jab presents less harm for patients than the virus itself, study reveals

It comes amid previous concerns about potential harm from the jab

The Independent UK

Covid-19 jab causes fewer problems than the virus itself in youngsters – study

The new study was led by experts at UCL and the universities of Cambridge and Edinburgh.

AAP

COVID jabs cut the risk of heart complications in kids

Vaccination has been associated with a smaller risk of rare heart conditions compared to COVID-19 infection in children, the largest study of its kind suggests.

Benzinga

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Benzinga

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.

Benzinga

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday.

The Independent UK

Pfizer COVID-19 vaccine sales drop 25% after confusing government guidance on the shot

Previously, fall is when Americans would typically receive their vaccines

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wall Street Journal

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.